What this band has actually done:
stocks scoring 25–45
beat the S&P 500 over the next three months
45.3%
of the time, across 39,662 cases
since 2015.
That is below a coin flip — and so is every other band, because the
median stock loses to a cap-weighted index.
How we measured this
Hedge funds
41
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$864M
Industry
Biotechnology
Sector
Healthcare
Exchange
NYSE
About GINKGO BIOWORKS HOLDINGS INC
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also…
Who's behind the signal
Every informed buyer we can see on DNA, across all three feeds.
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
GINKGO BIOWORKS HOLDINGS INC isn't in the top-10 model right now, but 8 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
8
Investors
1
New positions
4
Increasing
1
Decreasing
2
Unchanged
Price History
Loading price data...
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to GINKGO BIOWORKS HOLDINGS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell GINKGO BIOWORKS HOLDINGS INC or any security.